Is Cryosite a good dividend stock?

Cryosite (ASX:CTE) pays an annual dividend of A$0.07 per share and currently has a dividend yield of 9.42%. CTE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 233.33%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for CTE .

ASX:CTE

Cryosite (CTE) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CTE Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 418 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 9.42%
Price Target: N/A

Stock Analysis

Get Cryosite alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cryosite Stock (ASX:CTE)

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

CTE Stock News Headlines

March 21, 2024 | finance.yahoo.com

Here's Why Cryosite (ASX:CTE) Has Caught The Eye Of Investors

February 23, 2024 | finance.yahoo.com

A Look At The Fair Value Of Cryosite Limited (ASX:CTE)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 29, 2023 | uk.finance.yahoo.com

Non Executive Director of Cryosite Andrew Kroger Buys 12% More Shares

December 24, 2023 | finance.yahoo.com

Is Weakness In Cryosite Limited (ASX:CTE) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

August 25, 2023 | finance.yahoo.com

Cryosite Full Year 2023 Earnings: EPS: AU$0.029 (vs AU$0.028 in FY 2022)

July 16, 2023 | finance.yahoo.com

Cryosite Limited (ASX:CTE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

July 15, 2023 | sports.yahoo.com

CTE diagnosed in a female professional athlete for the first time

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

June 17, 2023 | abcnews.go.com

Henri 'Pocket Rocket' Richard, 11-time winner of Stanley Cup, diagnosed with CTE after death in 2020

June 17, 2023 | cnn.com

Experts say influential group’s guidance on CTE is too weak

June 3, 2023 | finance.yahoo.com

Insiders' AU$2.3m Investments In Red Following Cryosite's AU$10m Dip In Market Value

May 5, 2023 | usnews.com

Weslaco 21st Century Cte Early College High School

April 18, 2023 | usatoday.com

Louisville bank gunman's brain to be tested for CTE, lawyer says after shooting killed 5 people

April 1, 2023 | dailymail.co.uk

The Old Man and the CTE? Did the disease that haunts NFL lead Ernest Hemingway to suicide at 61?

March 3, 2023 | au.finance.yahoo.com

Cryosite Limited (CTE.AX)

February 18, 2023 | nj.com

Family of recently-deceased ex-NFL star donates his brain to CTE study

February 6, 2023 | finance.yahoo.com

Are Robust Financials Driving The Recent Rally In Cryosite Limited's (ASX:CTE) Stock?

December 24, 2022 | nz.finance.yahoo.com

Mark Kerr of Cryosite Limited (ASX:CTE) Just Spent AU$582k On Shares

August 26, 2022 | nz.finance.yahoo.com

Is Cryosite Limited's (ASX:CTE) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

August 18, 2022 | wsj.com

Cryosite Ltd.

August 9, 2022 | reuters.com

CTE.AX - Cryosite Limited | Stock Price & Latest News | Reuters

August 5, 2022 | nz.finance.yahoo.com

Stock Bulls Defy Bond Pessimism With Visions of Soft Landing

August 3, 2022 | finance.yahoo.com

Is Now The Time To Put Cryosite (ASX:CTE) On Your Watchlist?

June 3, 2022 | afr.com

Cryosite Limited

May 25, 2022 | msn.com

ASX Small Cap Lunch Wrap: Who can spot the elephant in the room today?

April 28, 2022 | finance.yahoo.com

A Cryosite Limited (ASX:CTE) insider increased their holdings by 11% last year

See More Headlines

Receive CTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryosite and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: ASX:CTE
CUSIP: N/A
CIK: N/A
Web: www.cryosite.com
Phone: 61 2 8865 2000
Fax: N/A
Employees: 25
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A$0.03
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.58 million
Net Margins: 12.49%
Pretax Margin: N/A
Return on Equity: 63.71%
Return on Assets: 5.17%

Debt

Debt-to-Equity Ratio: 87.26
Current Ratio: 2.32
Quick Ratio: 1.76

Sales & Book Value

Annual Sales: $12.62 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 0.55
Book Value: A$0.06 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 48,810,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.53

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Ms. Jane Hao
Chief Financial Officer
Mr. Jon Stearns
Operations Manager
Ms. Alicia Steel
Chief Quality Officer
Mr. Dray Andrea
Company Secretary

Key Competitors

View All Competitors

Insiders

Andrew Kroger
Sold 500,000 shares
Total: $300,000.00 ($0.60/share)

CTE Stock Analysis - Frequently Asked Questions

Is Cryosite a good dividend stock?: Cryosite (ASX:CTE) pays an annual dividend of A$0.07 per share and currently has a dividend yield of 9.42%. CTE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 233.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for CTE.

This page (ASX:CTE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial